Does the current treatment of invasive fungal infection need to be reviewed?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 32, Issue 8, 2014, Pages 523-528

  Martín Peña, Almudena ^a,b   Aguilar Guisado, Manuela ^a,b   Cisneros, José Miguel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Spanish Network for Research in Infectious Diseases ^*  (Spain)

Author keywords

Antifungal consumption; Antifungal therapy; Invasive fungal infection

Indexed keywords

ANTIFUNGAL AGENT; AMPHOTERICIN; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PLACEBO; POSACONAZOLE; VORICONAZOLE;

CRITICALLY ILL PATIENT; FEVER; HEALTH CARE; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MORTALITY; NEUTROPENIA; PROPHYLAXIS; REVIEW; SUPERINFECTION; SYSTEMIC MYCOSIS; CANDIDEMIA; COMBINATION CHEMOTHERAPY; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION PREVENTION; MONOTHERAPY; ANTIFUNGAL RESISTANCE; CANDIDIASIS, INVASIVE; CLINICAL TRIAL (TOPIC); COMPLICATION; CRITICAL ILLNESS; DISEASE MANAGEMENT; DRUG UTILIZATION; HEMATOLOGIC DISEASE; INVASIVE PULMONARY ASPERGILLOSIS; MYCOSES; NEOPLASM; RISK FACTOR; TRENDS;

ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; DISEASE MANAGEMENT; DRUG RESISTANCE, FUNGAL; DRUG UTILIZATION; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MYCOSES; NEOPLASMS; NEUTROPENIA; RISK FACTORS;

EID: 84907394269     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2013.02.008     Document Type: Review

References (69)

1. D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, and J. Fishman Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry Clin Infect Dis 48 2009 265 273
2. P.G. Pappas, B.D. Alexander, D.R. Andes, S. Hadley, C.A. Kauffman, and A. Freifeld Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) Clin Infect Dis 50 2010 1101 1111
3. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
4. L. Pagano, M. Caira, A. Candoni, M. Offidani, L. Fianchi, and B. Martino The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study Haematologica 91 2006 1068 1075
5. L. Pagano, M. Caira, A. Nosari, M.T. Van Lint, A. Candoni, and M. Offidani Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne Clin Infect Dis 45 2007 1161 1170
6. R. Martino, M. Subirá, M. Rovira, C. Solano, L. Vázquez, and G.F. Sanz Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients Br J Haematol 116 2002 475 482
7. D.P. Kontoyiannis, K.A. Marr, B.J. Park, B.D. Alexander, E.J. Anaissie, and T.J. Walsh Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database Clin Infect Dis 50 2010 1091 1100
8. A. Upton, K.A. Kirby, P. Carpenter, M. Boeckh, and K.A. Marr Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality Clin Infect Dis 44 2007 531 540
9. M. Caira, C. Girmenia, R.M. Fadda, M.E. Mitra, M. Picardi, and M.T. Van Lint Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 81 2008 242 243
10. D.H. Kett, E. Azoulay, P.M. Echeverria, and J.-L. Vincent Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study Crit Care Med 39 2011 665 670
11. A.M. Tortorano, G. Dho, A. Prigitano, G. Breda, A. Grancini, and V. Emmi Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008) Mycoses 55 2012 73 79
12. D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, and J.H. Rex Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin Infect Dis 54 2012 1110 1122
13. T.J. Walsh, H. Teppler, G.R. Donowitz, J.A. Maertens, L.R. Baden, and A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
14. T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, and J. Raffalli Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
15. T.J. Walsh, R.W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, and D. Bodensteiner Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 1999 764 771
16. S. Berdaguer, J. Bautista, M. Brunet, and J.M. Cisneros Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients Enferm Infecc Microbiol Clin 30 Suppl. 2 2012 86 92
17. M. Bassetti, F. Ansaldi, L. Nicolini, E. Malfatto, M.P. Molinari, and M. Mussap Incidence of candidaemia and relationship with fluconazole use in an intensive care unit J Antimicrob Chemother 64 2009 625 629
18. I. Oren Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia Clin Infect Dis 40 2005 770 771
19. K. De With, M. Steib-Bauert, H. Knoth, F. Dörje, E. Strehl, and U. Rothe Hospital use of systemic antifungal drugs BMC Clin Pharmacol 5 2005 1
20. M.D. Johnson, M. Kleinberg, L. Danziger, and L. Ostrosky-Zeichner Pharmacoeconomics of antifungal pharmacotherapy - challenges and future directions Expert Opin Pharmacother 6 2005 2617 2632
21. Red Española de Investigación en Patología Infecciosa [Spanish Network for Research in Infectious Pathology]. Consumo de Antimicrobianos [Internet] [cited January 8, 2013]. Available from: http://www.reipi.org/index.php/es/noticias-no-borrar/122-consumo-de-antimicrobianos.
22. A.L. Pakyz, H.E. Gurgle, and M.J. Oinonen Antifungal use in hospitalized adults in U.S. academic health centers Am J Health Syst Pharm 68 2011 415 418
23. Y. Nivoix, A. Launoy, P. Lutun, J.-C. Moulin, K.-A. Phai Pang, and L.-M. Fornecker Adherence to recommendations for the use of antifungal agents in a tertiary care hospital J Antimicrob Chemother 67 2012 2506 2513
24. M. Hoenigl, I. Zollner-Schwetz, H. Sill, W. Linkesch, C. Lass-Flörl, and W.J. Schnedl Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies Mycoses 54 2011 454 459
25. M.J. Rodríguez-Hernández, M. Ruiz-Pérez de Pipaon, M. Márquez-Solero, P. Martín-Rico, J.J. Castón-Osorio, and F.M. Guerrero-Sánchez Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain) Enferm Infecc Microbiol Clin 29 2011 328 333
26. O. Lortholary, J.-P. Gangneux, K. Sitbon, B. Lebeau, F. De Monbrison, and Y. Le Strat Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007) Clin Microbiol Infect 17 2011 1882 1889
27. P.M. Olaechea-Astigarraga, F. Alvarez-Lerma, M. Palomar-Martínez, J. Insausti-Ordeñana, M.J. López-Pueyo, and I. Seijas-Betolaza Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010 Enferm Infecc Microbiol Clin 30 2012 435 440
28. H.C. Standiford, S. Chan, M. Tripoli, E. Weekes, and G.N. Forrest Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program Infect Control Hosp Epidemiol 33 2012 338 345
29. J.M. Aguado, I. Ruiz-Camps, P. Muñoz, J. Mensa, B. Almirante, and L. Vázquez Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update Enferm Infecc Microbiol Clin 29 2011 345 361
30. J. Fortún, J. Carratalá, J. Gavaldá, M. Lizasoain, M. Salavert, and R. De la Cámara Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update Enferm Infecc Microbiol Clin 29 2011 435 454
31. J. Maertens, O. Marchetti, R. Herbrecht, O.A. Cornely, U. Flückiger, and P. Frêre European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 - 2009 update Bone Marrow Transplant 46 2011 709 718
32. A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, M.J. Boeckh, J.I. Ito, and C.A. Mullen Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America Clin Infect Dis 52 2011 56 93
33. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, and J.E. Edwards Jr. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
34. P.A. Pizzo, K.J. Robichaud, F.A. Gill, and F.G. Witebsky Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia Am J Med 72 1982 101 111
35. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group Am J Med 86 1989 668 672
36. M.H. White, R.A. Bowden, E.S. Sandler, M.L. Graham, G.A. Noskin, and J.R. Wingard Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia Clin Infect Dis 27 1998 296 302
37. D.J. Winston, J.W. Hathorn, M.G. Schuster, G.J. Schiller, and M.C. Territo A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer Am J Med 108 2000 282 289
38. J.R. Wingard, M.H. White, E. Anaissie, J. Raffalli, J. Goodman, and A. Arrieta A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 2000 1155 1163
39. M. Boogaerts, D.J. Winston, E.J. Bow, G. Garber, A.C. Reboli, and A.P. Schwarer Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial Ann Intern Med 135 2001 412 422
40. J. Maertens, K. Theunissen, G. Verhoef, J. Verschakelen, K. Lagrou, and E. Verbeken Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41 2005 1242 1250
41. J.M. Cisneros, I. Espigado, A. Rivero, F. Lozano de León, J. Parra, and A.R. Collado Empirical antifungal therapy in selected patients with persistent fever and neutropenia Enferm Infecc Microbiol Clin 23 2005 609 614
42. E. Jantunen, J. Salonen, E. Juvonen, E. Koivunen, T. Siitonen, and T. Lehtinen Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients Eur J Haematol 73 2004 174 178
43. M. Kawazu, Y. Kanda, Y. Nannya, K. Aoki, M. Kurokawa, and S. Chiba Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 → 3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders J Clin Microbiol 42 2004 2733 2741
44. J. Maertens, K. Theunissen, E. Verbeken, K. Lagrou, J. Verhaegen, and M. Boogaerts Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients Br J Haematol 126 2004 852 860
45. K. Oshima, Y. Kanda, Y. Asano-Mori, N. Nishimoto, S. Arai, and S. Nagai Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients J Antimicrob Chemother 60 2007 350 355
46. F.L. Dignan, S.O. Evans, M.E. Ethell, B.E. Shaw, F.E. Davies, and C.E. Dearden An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality Bone Marrow Transplant 44 2009 51 56
47. M. Aguilar-Guisado, I. Espigado, E. Cordero, M. Noguer, R. Parody, and J. Pachón Empirical antifungal therapy in selected patients with persistent febrile neutropenia Bone Marrow Transplant 45 2010 159 164
48. C. Girmenia, A. Micozzi, G. Gentile, S. Santilli, E. Arleo, and L. Cardarelli Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study J Clin Oncol 28 2010 667 674
49. C. Cordonnier, C. Pautas, S. Maury, A. Vekhoff, H. Farhat, and F. Suarez Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial Clin Infect Dis 48 2009 1042 1051
50. M. Aguilar-Guisado, A. Martin-Pena, I. Espigado, M. Ruiz Perez de Pipaon, J. Falantes, and F. De la Cruz Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach Haematologica 97 2012 464 471
51. M. Morrell, V.J. Fraser, and M.H. Kollef Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 2005 3640 3645
52. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, and R.S. Turpin Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 43 2006 25 31
53. M.G. Schuster, J.E. Edwards Jr., J.D. Sobel, R.O. Darouiche, A.W. Karchmer, and S. Hadley Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial Ann Intern Med 149 2008 83 90
54. A. Laín, N. Elguezabal, M.D. Moragues, J.C. García-Ruiz, A. Del Palacio, and J. Pontón Contribution of serum biomarkers to the diagnosis of invasive candidiasis Expert Rev Mol Diagn 8 2008 315 325
55. M. Mikulska, T. Calandra, M. Sanguinetti, D. Poulain, and C. Viscoli The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia Crit Care 14 2010 222
56. L. Lehtonen, V.J. Anttila, T. Ruutu, J. Salonen, J. Nikoskelainen, and E. Eerola Diagnosis of disseminated candidiasis by measurement of urine d-arabinitol/l-arabinitol ratio J Clin Microbiol 34 1996 2175 2179
57. D. Pittet, M. Monod, P.M. Suter, E. Frenk, and R. Auckenthaler Candida colonization and subsequent infections in critically ill surgical patients Ann Surg 220 1994 751 758
58. R. Piarroux, F. Grenouillet, P. Balvay, V. Tran, G. Blasco, and L. Millon Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients Crit Care Med 32 2004 2443 2449
59. C. León, S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, and F. Alvarez-Lerma A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization Crit Care Med 34 2006 730 737
60. L. Ostrosky-Zeichner, C. Sable, J. Sobel, B.D. Alexander, G. Donowitz, and V. Kan Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting Eur J Clin Microbiol Infect Dis 26 2007 271 276
61. B.J. Kullberg, P.E. Verweij, M. Akova, M.C. Arendrup, J. Bille, and T. Calandra European expert opinion on the management of invasive candidiasis in adults Clin Microbiol Infect 17 Suppl. 5 2011 1 12
62. E.-R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadharao Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
63. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
64. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
65. J.M. Cisneros, O. Neth, and J. Pachón Selection bias in Andes et al. Clin Infect Dis 55 2012 893 894
66. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, and K.A. Marr Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360
67. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, and J.-W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
68. M.A. Garbati, F.A. Alasmari, M.A. Al-Tannir, and I.M. Tleyjeh The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review Int J Infect Dis 16 2012 76 81
69. K.A. Marr, H. Schlamm, S.T. Rottinghaus, S. Jagannatha, E.J. Bow, and J.R. Wingard A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis Clin Microbiol Infect 18 Suppl. 3s 2012 713